ED
MXIM

Exane Derivatives’s Maxim Integrated Products MXIM Stock Holding History

Exane Derivatives’s Portfolio MXIM Stock Details MXIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-396
Closed -$15.3K – 700
2016
Q4 		$15.3K Hold
396
– – ﹤0.01% 382
2016
Q3 		$15.8K Hold
396
– – ﹤0.01% 379
2016
Q2 		$14.1K Buy
+396
New +$14.5K ﹤0.01% 353

Other funds holding MXIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Exane Derivatives's MXIM Position: Q1 2017 in Review

Exane Derivatives sold out of Maxim Integrated Products (MXIM) in Q1 2017, closing a stake of 396 shares — an estimated $15.3K sold.

Exane Derivatives first reported a position in MXIM in Q2 2016 and held it in 3 quarters. The position peaked at $15.8K in Q3 2016. 443 funds tracked by Wall St. Rank hold MXIM as of Q1 2017.

  • Exane Derivatives reported no remaining Maxim Integrated Products position as of Q1 2017 after selling out during the quarter.
  • Exane Derivatives sold 396 Maxim Integrated Products shares in Q1 2017, an estimated $15.3K.
  • Exane Derivatives first reported a position in Maxim Integrated Products in Q2 2016 and held it in 3 quarters.
  • Exane Derivatives's Maxim Integrated Products position peaked at $15.8K in Q3 2016.
  • 443 funds tracked by Wall St. Rank held Maxim Integrated Products as of Q1 2017.

Based on Exane Derivatives's 13F filing for Q1 2017, filed 28 Apr 2017.